Researchers have developed the first reliable test for new variant Creutzfeldt-Jakob disease (CJD) that can be used while the patient is still alive. Details are revealed in this week's Lancet. The test, developed under John Collinge at Imperial College, London, identifies rogue prion proteins in tonsil tissue and means doctors could test the general population.
Register to continue
Why register?
- Registration is free and only takes a moment
- Once registered, you can read 3 articles a month
- Sign up for our newsletter
Subscribe
Or subscribe for unlimited access to:
- Unlimited access to news, views, insights & reviews
- Digital editions
- Digital access to THE’s university and college rankings analysis
Already registered or a current subscriber? Login